Sanofi’s Stock Declines Despite Positive Trial Results and Strategic Moves
Sanofi’s stock price has declined by 5% despite positive developments, including successful trials and a strategic acquisition, as investors remain cautious about the company’s growth prospects.
2 minutes to read